Ivan Krečak
Impact in
- Genetics top 5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Hematology top 10%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Papers in
- Genetics 39
- Myeloproliferative Neoplasms: Diagnosis and Treatment 36
- Hemoglobinopathies and Related Disorders 7
- Hematology 19
- Acute Myeloid Leukemia Research 9
- Chronic Myeloid Leukemia Treatments 6
- Multiple Myeloma Research and Treatments 4
- Co-authors
- Marko Lucijanić (34 shared papers)Srđan Verstovšek (5 shared papers)Marko Skelin (9 shared papers)Rajko Kušec (10 shared papers)Tajana Štoos‐Veić (3 shared papers)Ksenija Fumić (2 shared papers)Kenneth Bryan (1 shared paper)Vlatko Pejša (2 shared papers)
- Journals
- Biomedicines (4 papers)HemaSphere (4 papers)Life (2 papers)Blood (2 papers)Cancers (2 papers)
- Partner nations
- CroatiaUnited StatesSerbia
In The Last Decade
Ivan Krečak
50 papers receiving 209 citations
Peers
Comparison fields: 5 of 38
- Genetics 150
- Hematology 71
- Rheumatology 62
- Internal Medicine 3
- Nephrology 6
Countries citing papers authored by Ivan Krečak
This map shows the geographic impact of Ivan Krečak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Krečak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Krečak more than expected).
Fields of papers citing papers by Ivan Krečak
This network shows the impact of papers produced by Ivan Krečak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Krečak. The network helps show where Ivan Krečak may publish in the future.
Co-authors
The 25 scholars most cited alongside Ivan Krečak, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 58 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 19 | |
| 2 | 2020 | 17 | |
| 3 | 2022 | 16 | |
| 4 | 2020 | 16 | |
| 5 | 2021 | 10 | |
| 6 | 2022 | 10 | |
| 7 | 2019 | 9 | |
| 8 | 2020 | 7 | |
| 9 | 2023 | 7 | |
| 10 | 2023 | 7 | |
| 11 | 2023 | 6 | |
| 12 | 2023 | 6 | |
| 13 | 2024 | 6 | |
| 14 | 2021 | 6 | |
| 15 | 2023 | 5 | |
| 16 | 2023 | 5 | |
| 17 | Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasms. | 2023 | 5 |
| 18 | 2024 | 4 | |
| 19 | 2022 | 4 | |
| 20 | 2018 | 4 |
About Ivan Krečak
Ivan Krečak is a scholar working on Genetics, Hematology, Molecular Biology, Rheumatology and Oncology, having authored 58 papers that have together received 210 indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (36 papers), Acute Myeloid Leukemia Research (9 papers), Hemoglobinopathies and Related Disorders (7 papers), Eosinophilic Disorders and Syndromes (7 papers), Kruppel-like factors research (6 papers), Chronic Myeloid Leukemia Treatments (6 papers), COVID-19 Clinical Research Studies (5 papers) and Multiple Myeloma Research and Treatments (4 papers). The work is most often cited by research in Genetics (150 citations), Hematology (71 citations), Rheumatology (62 citations), Internal Medicine (3 citations) and Nephrology (6 citations). Ivan Krečak has collaborated with scholars based in Croatia, United States and Serbia. Frequent co-authors include Marko Lucijanić, Srđan Verstovšek, Marko Skelin, Rajko Kušec, Tajana Štoos‐Veić, Ksenija Fumić, Kenneth Bryan, Vlatko Pejša, Ivan Samarđžić and Mike W. Zuurman. Their work appears in journals such as Biomedicines, HemaSphere, Life, Blood and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.